Chennai – USV Pvt Ltd, recently launched Q rite tablets, containing 200 milligrams (mg) of Quinidine Sulphate for patients with rare irregular heartbeat conditions. This launch marks the much-needed commercial availability of Quinidine Sulphate tablets in India. This significant milestone underscores USV’s commitment to advancing quality patient care as a reliable health care partner.
India faces one of the highest burdens of cardiovascular diseases (CVD) globally. Approximately 40% of cardiac patients show signs of heart rhythm disorders, with a concerning 22% at increased risk of sudden cardiac arrest due to arrhythmia. Alarmingly, most of these patients are under the age of 40. Keeping this overlooked demographic in mind, USV took the step to commercially launch Q rite tablets in India, to improve patient outcomes.
Mr Prashant Tewari, Managing Director, USV “We have been empathetic to the needs of patients especially individuals with cardiac conditions and do not have an option for its management, the launch of Q rite tablets in India underscores our vision of enhancing accessibility. We believe our commitment to niche medication will offer targeted solutions that significantly improves patient outcomes.”
Elaborating on the importance of the launch, Dr. Aditya Kapoor, President of Indian Society of Electrocardiology (ISE) and Dr. Ketan Mehta, Honorary General-Secretary (ISE) mentioned in a joint statement that “Quinidine being an old yet versatile multipurpose antiarrhythmic drug, its availability in India shall adequately address the need of a select group of patient population.”
Q rite tablets is currently available at pharmacies in select hospitals and through online pharmaceutical retailer Tata 1mg.
